Takeda Pharmaceutical Company Limited

Hidekazu Tokuhara

Yoshiyuki Fukase

Atsuko Ochida

Satoshi Yamamoto

Tsuneo Oda

Naoki Ishii

Junya Shirai

Shoji Fukumoto

Yoshihide Tomata

Mitsunori Kono

Takashi Imada

Hideyuki Sugiyama

Takanobu Kuroita

Minoru Nakamura

Toshio Tanaka

Koji Ono

Masahiro Ito

Takeshi Yamamoto

Yasuhiro Imaeda

Tomoya Yukawa

Michiko Tawada

Shuhei Ikeda

Jumpei Aida

Kouichi Iwanaga

Naohiro Taya

Hiroshi Banno

Tomohiro Okawa

Yasuyoshi Arikawa

Masataka Murakami

Takaharu Hirayama

Ayumu Sato

Yusuke Sasaki

Tatsuki Koike

Makoto Kamata

Yuya Oguro

Hironobu Maezaki

Yasuhiro Hirata

Makoto Fushimi

Nobuki Sakauchi

Tomokazu Kusumoto

Nobuo Cho

Moriteru Asano

Ryo Mizojiri

Douglas Robert Cary

Akinori Toita

Hironori Kokubo

Jun Fujimoto

Nao Morishita

Yasushi Hattori

Shinji Nakamura

Hideo Suzuki

Xin Liu

Masami Yamada

Shinichi Imamura

Hiroyuki Watanabe

Yoshiteru Ito

Kazuaki Takami

Tomoaki Hasui

Satoshi Mikami

Shinji Morimoto

Tohru Yamashita

Rei Okamoto

Noriyuki Nii

Nobuyuki Matsunaga

Youichi Kawakita

Kouhei Asano

Masako Miyazaki

Norio Oyabu

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I):

Nitrogen containing heterocycles as CDK12 inhibitors

The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.

Heterocyclic amide compounds having an RORvt inhibitory action

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic compound

The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function

The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

The present invention relates to compound (I) or a salt thereof which has a ROR&#x3b3;t inhibitory action. In the formula (I), each symbol is as defined in the specification. 

Heterocyclic amide compounds having RORyT inhibitory action

The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): 

Amide compound

The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates a compound represented by the formula (I): wherein each symbol is as described in the specification,or a salt thereof.

Provided are heterocyclic compounds having a ROR&#x3b3;t inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. 

Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors

The present invention relates to compound (I) or a salt thereof which has a ROR&#x3b3;t inhibitory action. wherein each symbol is as defined in the specification.

The present invention provides a heterocyclic compound having a ROR&#x3b3;t inhibitory action. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.or a salt thereof.

Growing community of inventors

Kanagawa, Japan

Hidekazu Tokuhara